Assessment of renal abnormalities in 107 HIV patients treated with tenofovir;Evaluation de la tolérance rénale du ténofovir dans une cohorte de 107 patients

Therapie

Volumn 60, Issue 2, 2005, Pages 175-181

  Lochet, Pierre ^a   Peyrière, Helène ^b   Le Moing, Vincent ^a   Blayac, Jean Pierre ^b   Hansel, Sylvie ^b   Reynes, Jacques ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

Fanconi syndrom; HIV; Hypophosphataemia; Nephrotoxicity; Renal abnormalities; Tenofovir

Indexed keywords

ANTIRETROVIRUS AGENT; CREATININE; GLUCOSE; LOPINAVIR; PHOSPHATE; PROTEIN; RITONAVIR; TENOFOVIR;

ADULT; AGED; CLINICAL OBSERVATION; CONFERENCE PAPER; CREATININE CLEARANCE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT;

EID: 18244405771     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2005022     Document Type: Conference Paper

References (25)

1. Chapman T, McGavin J, Noble S. Tenofovir disoproxil fumarate. Drugs 2003; 63: 1597-608
2. De Clercq E. Antiviral drugs: current state of the art. J Clin Virol 2001; 22: 73-89
3. Antoniou T. Park-Wyllie L, Tseng A. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 2003; 23: 29-43
4. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20: 641-8
5. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy. J Acqur Immune Defic Syndr 2004; 35: 269-73
6. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18: 1074-5
7. Caspar G, Monereo A, Garcia-Reyne A, et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004; 18: 351-2
8. Karras AA, Lafaurie M, Furco A, et al. Tenofovir related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-3
9. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40: 1331-3
10. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1 positive patient treated with tenofovir. AIDS 2003; 17: 935-7
11. Coca S, Perazella MA. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-4
12. Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37: 41-3
13. Anonyme. Echelle ANRS de cotation de la gravité des événements indésirables chez l'adulte. Version n°4, octobre 2000 [online]. Available from URL: http://www.anrs.fr/index.php/article/ articleview/1331/1/42 [Accessed 2005 Mar 16]
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
15. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-63
16. Isnard-Bagnis C, Tezenas du Montcel S, Fonfrede M, et al. Prevalence of electrolyte and acid base disorders in HIV patients [abstract SA-PO890]. J Am Soc Nephrol 2002; 13: 448A
17. Squires K, Pozniak AL. Pierone Jr G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139: 313-20
18. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43: 595-612
19. Kronenberg HM. NPT2a: the key to phosphate homeostasis. N Engl J Med 2002; 347: 1022-4
20. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course and management. Clin Infect Dis 2001; 33: 115-9
21. Gardner LI, Holmberg SD, Williamson JM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV infected women. J Acquir Immune Defic Syndr 2003; 32 (2): 203-9
22. Crowther MA, Callaghan W, Hodsman AB, et al. Dideoxyinosine-associated nephrotoxicity. AIDS 1993; 7: 131-2
23. Scott JD, Wolfe PR, Quiros J, et al. Rare occurrence of renal toxicity when retrospectively evaluating the use of tenofovir DF in 2 clinical practices [abstract TuPeB4632]. XV International AIDS Conference; 2004 Jul 11-16; Bangkok [online]. Available from URL: http://www.ejias.org [Accessed 2005 Mar 16)
24. Jaegel-Guedes E, Wolf E, Ruemmelein N, et al. Incidence of tenofovir-related nephrotoxicity in a large outpatient cohort [abstract WePeB5937]. XV International AIDS Conference; 2004 Jul 11-16; Bangkok [online]. Available from URL: http://www.ejias.org [Accessed 2005 Mar 16)
25. Mauss S, Berger F, Carls H, et al. Tenofovir is associated with mild renal dysfunction [abstract WePeB5941]. XV International AIDS Conference; 2004 Jul 11-16; Bangkok [online]. Available from URL: http://www.ejias.org [Accessed 2005 Mar 16)